赫兰提斯·法尔马(Herantis Pharma)的帕金森(Parkinson)药“HER-096”在早期试验中显示出希望,而其他疗法尽管有些失败,但还是取得了进步。 Herantis Pharma's Parkinson’s drug HER-096 shows promise in early trials, while other therapies advance, despite some failures.

据Herantis Pharma报告,Parkinson病人的1b阶段取得了积极结果,显示安全性、可耐性和血脑屏障渗透率,为2026年计划中的第二阶段试验选择了300毫克剂量。 Herantis Pharma reports positive Phase 1b results for HER-096 in Parkinson’s patients, showing safety, tolerability, and blood-brain barrier penetration, with the 300 mg dose selected for a planned Phase 2 trial in 2026. 同时,Bayer和BlueRock治疗公司宣布,第一阶段对Bemdaneprocel(一种基于干细胞的疗法)试验的36个月安全数据有利于Bemdaneprocel,支持其进入后期测试。 Meanwhile, Bayer and BlueRock Therapeutics announce favorable 36-month safety data from a Phase I trial of bemdaneprocel, a stem cell-based therapy, supporting its advancement to later-stage testing. 尽管AstraZeneca的exenatide和UCB的minzasolmin等候选药物出现挫折,帕金森病的研究仍在积极进行,全球有100多种治疗方法正在开发中,其中一些已进入第三阶段,包括罗氏的prasinezumab和BlueRock的bemdaneprocel. Despite setbacks for some candidates like AstraZeneca’s exenatide and UCB’s minzasolmin, Parkinson’s research remains active, with over 100 therapies in development globally and several advancing to Phase III, including Roche’s prasinezumab and BlueRock’s bemdaneprocel.